NCT03798626 2026-01-27Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersNovartisPhase 1 Completed167 enrolled
NCT00082706 2025-09-09Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal RemnantM.D. Anderson Cancer CenterPhase 2 Active not recruiting46 enrolled
NCT03872947 2025-08-03A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, IncPhase 1 Active not recruiting138 enrolled
NCT05714553 2025-07-18NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNuCana plcPhase 1/2 Terminated19 enrolled
NCT03197571 2025-02-21QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyImmunityBio, Inc.Phase 1/2 Withdrawn
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT00957905 2017-03-10Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell TumorsNational Cancer Institute (NCI)Phase 2 Completed36 enrolled 7 charts
NCT01183663 2016-06-03Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)M.D. Anderson Cancer CenterPhase 1 Completed180 enrolled